The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.

AASM recommends against use of combination of CBT-I plus medication over CBT-I alone for chronic insomnia disorder.

Nereus ™ (tradipitant) is now available for the prevention of vomiting induced by motion in adults. According to manufacturer Vanda Pharmaceuticals, the product is available by ...

Despite earlier antibiotic exposure being more common in those with celiac disease, researcher says 'the connections are much more complex' ...

Patients treated with dilanubicel demonstrated faster hematopoietic recovery and had a markedly lower incidence of severe acute GVHD. HealthDay News — Adding dilanubicel, a cryopreserved, cord blood ...

Radiomics-based early detection model surpasses radiologists for detecting PDA at visually occult prediagnostic stage.

Credit: Novo Nordisk. The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral ...

Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is noninferior to continuing current antiretroviral therapy.

The Food and Drug Administration (FDA) has approved Auvelity ® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer d ...

HealthDay News — Dietary and lifestyle modifications are reasonable first-line therapies for symptomatic hemorrhoids, according to a clinical practice update issued by the American Gastroenterological ...

An independent safety monitoring board determined the study participant's death was unrelated to evenamide. The Food and Drug Administration (FDA) has placed a hold on the enrollment of new patients ...